- $17.22m
- $9.52m
- $0.40m
Annual balance sheet for iBio, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 97 | 33.5 | 4.3 | 14.2 | 8.58 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5.53 | 6.1 | 0.204 | 0.713 | 0.105 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 105 | 45.1 | 26.3 | 15.7 | 9.72 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 34.7 | 41.8 | 7.55 | 6.37 | 5.28 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 147 | 99.4 | 41.2 | 28.7 | 23.2 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.64 | 30.4 | 21.6 | 3.84 | 6.11 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 38.4 | 35.9 | 25.8 | 7.41 | 8.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 109 | 63.5 | 15.4 | 21.3 | 14.9 |
| Total Liabilities & Shareholders' Equity | 147 | 99.4 | 41.2 | 28.7 | 23.2 |
| Total Common Shares Outstanding |